Retrospective Analysis of the Pharmaco-Utilization of VEGF Inhibitors and Health Care Costs among Patients with Wet Age-Related Macular Degeneration and Other Ocular Diseases in Italy.

Int J Environ Res Public Health · 2022 · PMC8909764 · PMID 35270241

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Although a recent analysis on the use of anti-VEGF agents among Italian wAMD patients conducted by AIFA showed that almost half of treatments (44.6%) were with Ranibizumab, followed by Aflibercept (33.1%), but starting from 2016 to 2019, Aflibercept showed an increasing trend with the anti-VEGF having the highest number of eye treatments/month, while Ranibizumab use remained constant [ 8 , 14 ].

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.